

PREVENIR 4 - Persistence of evidence-based medical therapies over time in patients monitored by cardiologists after a first recent ACS

Head :Amelineau Élisabeth, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Last update : 09/05/2017 | Version : 2 | ID : 138

General

Identification

Detailed name Persistence of evidence-based medical therapies over time in patients monitored by cardiologists after a first recent ACS

Sign or acronym PREVENIR 4

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL N°833542 version 8

General Aspects

Medical area Cardiology

Health determinants Medicine

Keywords secondary prevention, persistence, care

Scientific investigator(s) (Contact)

Name of the director Amelineau

Surname Élisabeth

Address 3, rue J. Monier - 92500 Rueil Malmaison

Phone +33 (0)1 58 83 60 00

Email elisabeth.amelineau@bms.com

Unit Bristol-Myers Squibb

Name of the director Schmidely

Surname Nathalie

Address	3, rue J. Monier - 92500 Rueil Malmaison
Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb

Collaborations

Funding

Funding status	Private
----------------	---------

Details	Bristol-Myers Squibb France
---------	-----------------------------

Governance of the database

Sponsor(s) or organisation(s) responsible	Bristol-Myers Squibb France (BMS)
Organisation status	Private

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	random sampling in clusters.

Database objective

Main objective	Describe the persistence of secondary prevention therapeutics, between 3 and 18 months after hospitalization for a first acute coronary syndrome (ACS), in patients monitored by private or hospital cardiologists
----------------	--

Inclusion criteria	M/F \geq 18 years, outpatient seen in cardiology consultation, hospitalized in 2005 for a first ACS
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Metropolitan France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2006
Date of last collection (YYYY or MM/YYYY)	2007
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1801
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Biological data
Clinical data (detail)	Direct physical measures
Biological data (detail)	total cholesterol, HDL, LDL, Triglycerides, glycemia
Presence of a biobank	No
Health parameters studied	Health care consumption and services

Care consumption (detail)

Medicines consumption

Procedures

Data collection method

Paper CRF

Participant monitoring

No

Links to administrative sources

No

Promotion and access

Promotion

Link to the document

[http://www.ncbi.nlm.nih.gov/pubmed/?term=PREVENIR+AND+Amelineau+E\[Author\]](http://www.ncbi.nlm.nih.gov/pubmed/?term=PREVENIR+AND+Amelineau+E[Author])

Access

Terms of data access (charter for data provision, format of data, availability delay)

Publications

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only